Bitcoin price today: struggles at $111k as trade tensions, risk aversion weigh
Investing.com - BMO Capital has reiterated an Outperform rating and $75.00 price target on CRISPR Therapeutics (NASDAQ:CRSP), currently valued at $5.65 billion, following the company’s partnership with Sirius on FXI siRNA SRSD107. The stock has shown strong momentum, gaining over 50% in the past six months. According to InvestingPro data, analyst targets range from $32 to $268, reflecting diverse views on the company’s potential.
The partnership, which does not involve gene editing, has led to the initiation of a Phase II trial in venous thromboembolism (VTE) prevention, according to BMO Capital.
Clinical data from total knee arthroplasty (TKA) and atrial fibrillation (AF) studies suggest that FXI is a promising target that could disrupt the thromboembolism market valued at over $15 billion, which is currently dominated by Factor X-targeted products, primarily Eliquis.
BMO Capital notes that approximately 40% of atrial fibrillation patients remain under-treated or untreated, presenting a significant opportunity for new therapies in this space.
CRISPR Therapeutics’ small interfering RNA (siRNA) technology has the potential to deliver a best-in-class profile in the FXI space that could yield a multi-billion dollar commercial opportunity, with BMO Capital referencing Alnylam’s strong siRNA launch in the cardiovascular space as a comparable example.
In other recent news, CRISPR Therapeutics reported significant developments in its financial and clinical activities. The company announced that its second-quarter 2025 financial results included CASGEVY sales totaling $30 million, marking a 114% increase from the first quarter’s sales of $14 million. In clinical advancements, CRISPR Therapeutics, in partnership with Sirius Therapeutics, dosed the first patient in a Phase 2 clinical trial of SRSD107, a therapy for preventing venous thromboembolism in knee surgery patients. This trial aims to assess the safety and efficacy of SRSD107, which targets Factor XI to prevent pathological blood clot formation.
Analyst firms have also been active in updating their ratings on CRISPR Therapeutics. H.C. Wainwright reiterated its Buy rating and raised its price target to $80, highlighting potential future gains from the SRSD107 trial. Meanwhile, JPMorgan initiated coverage with an Overweight rating and a $70 price target, citing upcoming pivotal moments in the company’s portfolio. Barclays increased its price target to $56, maintaining an Equalweight rating, following updates on the company’s Casgevy treatment. These developments reflect a growing interest in CRISPR Therapeutics’ potential in both clinical and financial arenas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.